RESEARCH PAPER

Development and Evaluation of Advanced Insulin Delivery Systems for Improved Glycemic Control

Archana Shaha[1], Deepika Kumari[2], Rohith Krishnan M K[3], Niyamat Khan[4], Ritesh Kumar[5], Abdumuminov Boburbek[6], Pankaj Kumar[7*]

[1] Assistant Professor, Department of Pharmacy, Vishwakarma University, Pune - 411048.
Email: archana.shaha@gmail.com
[2] Research Scholar (pursuing PhD), Shri Venkateshwara University, Gajraula, Amroha, UP - 244236.
Email: deepikakumari0201@gmail.com
[3] Assistant Professor, Department of Anatomy, Fergana Medical Institute of Public Health, Yangituron Street 2a, Fergana. Email: Rohithkrishna743@gmail.com
[4] Assistant Professor, Department of Anatomy, Fergana Medical Institute of Public Health, Yangituron Street 2a, Fergana. Email: niyamatbalot870@gmail.com
[5] Associate Professor, Department of Pharmaceutics, Sharda School of Pharmacy, Sharda University Agra, Agra, Uttar Pradesh - 282007, India. ORCID: 0000-0003-2335-2570. Email: riteshiitbhu@gmail.com
[6] Assistant Professor, Department of Pathological Physiology and Pathological Anatomy, Ferghana Medical Institute of Public Health, Yangi turon 2A, 150100, Fergana. Email: abdumuminovbobur10@gmail.com
[7*] Principal, Aryans Pharmacy College, Rajpura, Punjab. (Corresponding Author)
Email: pankaj1981sameer@gmail.com

Received: 20th Feb, 2026 | **Revised:** 4th Mar, 2026 | **Accepted:** 25th Mar, 2026 | **Available Online:** 10th Apr, 2026

ABSTRACT

The human and financial cost of the global diabetes epidemic is tremendous, which is supported by comorbidities caused by the prolonged hyperglycemia. Although the landmark trials have demonstrated that tight glycemic control is the way to avoid complications, it is extremely difficult to do it with the traditional insulin treatment through multiple daily injections and using regular pumps. These are reactive open-loop systems that are highly mentally and cognitively taxing (diabetes distress) and are constrained by the risk of hypoglycemia leading to most people falling below targets. The development of highly sophisticated insulin delivery systems, especially closed-loop technology that is hybrid is a breakthrough. They combine an insulin pump, a control algorithm, and continuous glucose monitoring to produce an automated biofeedback loop. Such an active intervention can produce a greater glycemic outcome, better time-in-range and less hypoglycemia, and significantly ease the psychological load of daily management. Despite the challenges that are posed by the high initial cost and the fact that these systems require user involvement, these systems are beneficial in terms of cost-effectiveness in the long term since they help to avoid very costly complications. The future of diabetes care is characterized by constant evolution into fully automated systems, faster insulins and individually tailored algorithms. In the end, progressive delivery systems not only treat the physiological, psychological and economic aspects of diabetes but also provide a pivotal way of reducing the burden of diabetes in the world but also enabling people to live freer and more healthy lives.

Keywords: Diabetes mellitus, insulin delivery systems, glycemic control, hybrid closed-loop system, artificial pancreas, time-in-range (TIR), diabetes distress, insulin therapy.

How to cite this article: Shaha A, Kumari D, Rohith Krishnan MK, Khan N, Kumar R, Boburbek A, Kumar P. Development and Evaluation of Advanced Insulin Delivery Systems for Improved Glycemic Control. Int J Drug Deliv Technol. 2026;16(31s):331-344. DOI: 10.25258/ijddt.16.31s.41

Source of support: Nil.

Conflict of interest: The authors declare no conflict of interest.

Introduction

Diabetes is considered one of the most acute challenges in the sphere of the population health of the XXI century, and the prevalence rates increase to the level of an epigenic problem and present an unbelievable human and financial burden[1]. A leading cause of cardiovascular disease, kidney failure, blindness and amputation of lower limbs, diabetes is affecting more than half a billion adults across the globe today; its prevalence is expected to continue increasing inexorably. Its economic impact is titanic, taking hundreds of billions of dollars each year in direct medical expenses and lost productivity, a cost that is being felt with pain by both developed and more and more, developing countries[2]. Central to curbing this flood of complications is the need to have better glycemic control, i.e. the regulation of blood glucose levels as near to the nondiabetic level as possible. Those of them who have followed the evidence over decades, the majority of it based on groundbreaking studies such as the DCCT and UKPDS have conclusively shown that tight glycemic control lowers the risk of both microvascular and macrovascular complications by a significant margin. The realization of this control has always been blocked by the shortcomings of the traditional insulin therapy and therefore the development of sophisticated delivery mechanisms is not only a technological desire but also a moral and a feasible need[3][4]. Over decades, the classical approaches to intensive insulin therapy in type 1 diabetes and type 2 diabetes of an advanced type have been the multi-dose injections (MDI) and the traditional insulin pumps. Although superior to previous regimens, these strategies are essentially reactive and have great limitations which make the already hard to achieve near-physiological glycemic control quite cumbersome to maintain. MDI therapy, which consists of a daily dose of basal insulin injection (once or twice daily) and a dose of mealtime bolus insulin, induces a step-shaped insulin profile, which is not capable of replicating the minute-to-minute secretory accuracy of a normal pancreas. This is bound to cause a state of hyper- or hypoglycemia[5][6]. The cognitive and emotional load of manually calculating doses constantly, including blood glucose at that moment, estimated future intake of carbohydrates and exercise, causes decision fatigue, anxiety, and in most cases, the incorrect dosages. More importantly, both MDI and standard pump therapy work in an open-loop configuration: insulin is administered without any independent regulation according to the real-time glucose levels[7][8]. The individual with diabetes must even with the aid of the adjunct of continuous glucose monitoring (CGM) still needs to interpret the results, and make a response, which is a highly delay and inaccurate process especially when sleeping or when metabolic stress is unpredictable. The most dreaded and dangerous limitation is hypoglycemia particularly nocturnal and severe forms that serve as a limiting threshold to increasing therapy. Though they allow greater flexibility of base patterns and discrete delivery, standard pumps have this open-loop shortcoming and pose the risk of infusion set failure, site infection and ketoacidosis in circumstances where the flow of the insulin is disrupted. Therefore, the standard care presents a paradoxical burden of freedom so that the control mechanisms are there, but the physiological and mental complexity of implementing them at a perfect 24/7 is too much to handle and most people are unable to achieve recommended glycemic levels[9][10].

Table 1: Limitations of Conventional Insulin Delivery vs. Promise of Advanced Systems

Aspect	**Conventional Systems (MDI & Standard Pumps)**	**Advanced Delivery Systems (e.g., Hybrid Closed-Loop)**
Core Mechanism	Open-loop: Reactive, manual delivery.	Closed-loop: Proactive, automated algorithm-driven delivery.
Glycemic Outcomes	Suboptimal TIR & HbA1c for majority; significant hypoglycemia risk.	Increased TIR (+2.4 hrs/day in RCTs), reduced HbA1c, drastic cut in hypoglycemia.
Mental Burden	High "diabetes distress": Constant carb counting, dose calculations, and hypoglycemia anxiety.	Reduced burden: Automates micro-decisions; user shifts to supervisor role, alleviating anxiety.
Physiological Mimicry	Poor: Rigid basal profiles, delayed meal response.	Good: Dynamic, minute-to-minute basal adjustments; better overnight control (dawn phenomenon).

Key Limitation / Challenge	Hypoglycemia as a barrier to intensification; "burden of freedom."	High upfront cost; requires user trust and basic tech engagement; not fully autonomous for meals.
Economic Perspective	Lower upfront cost, but high long-term cost from complications.	High initial investment, but cost-effective long-term due to complication avoidance and productivity gains.



Fig: 1 Evolution of Insulin Delivery Technology

It is on this context of unremitting disease load and treatment inadequacy that the optimism of improved insulin delivery system, especially the hybrid closed-loop (HCL) system or artificial pancreas, is the paradigm shifting revolution[11][12]. Such systems constitute a radical shift of reactive, manual care to proactive, automated and adaptive treatment. They incorporate a continuous glucose monitor, a control algorithm on a smartphone or dedicated device, and an insulin pump into one, connected ecosystem, thereby forming a biofeedback loop that automatically alters the insulin delivery rate every few minutes in order to keep glucose levels within a target range. This promise is converted into practical life changing advantages in various dimensions. To begin with and most importantly, advanced systems have proven benefits in enhancing glycemic results[13]. Consistent and extensive clinical trials and real-world evidence demonstrate that time-in-range (TIR) increase, considerable HbA1c reduction, and, perhaps, most transformative, there is a radical decrease in both hypos and hyperglycemic variability. This unstoppable and noisy vigilance is particularly effective at night, as it does not allow to experience the phenomenon of the dawn, and patients and their families have their safety and sleep restored again[14][15]. Secondly, the systems deeply decrease the overwhelming mental and emotional load of diabetes, a phenomenon that is called diabetes distress. They relieve the cognitive bandwidth by automating the innumerable micro-decisions of day-to-day management, reducing the worry of hypoglycemia, and bringing an intense feeling of security[16]. The user is not driven out but up the ladder and is now supposed to be in a supervisory position of responding to the mealtime alerts and the system signals and not spending the entire time counting and worrying. This is an indescribable psychosocial advantage that can not only improve the quality of life, but also allow an individual to participate more in labor, family, and social activities. Third, this vow is transferred to health economics in the long term. Although high start-up expenses of advanced technology are high, there is a possibility of saving money when one avoids the expensive complications of diabetes, hospitalization due to severe cases of the disease (hypoglycemia or DKA), dialysis, cardiovascular surgeries and disability, making it a strong case of cost-efficiency over the lifetime of the patient. This is backed up by early economic models that indicate that closed-loop systems can be cost-effective indeed when all the spectrum of avoided complications and better productivity is considered[17]. In the future, the promise is developing at a high pace. More automation systems are replacing current hybrid systems, though still requiring mealtime bolus announcements, with more fully automated systems with the potential to include hormone combinations (such as glucagon) or faster-acting insulins capable of better managing both mealtime and exercise. It is expected to be integrated with other digital health platforms and utilize artificial intelligence to control and gain a personalized and predictive approach in the future. Finally, the overwhelming global diabetes crisis, which has been caused by the natural constraints of traditional insulin treatment, establishes an irresistible need to be innovative[18]. High-tech insulin delivery systems are living up to their original hype, not only with the promise of a little more of the same, but with a new definition of what can be achieved with diabetes care. They do this by automating glycemic control to deal with the physiological, psychological, and economic aspects of the illness, which is the most promising avenue to reducing the burden on the global population and giving individuals with diabetes an opportunity to lead safer and healthier and freer lives[19].

Pathophysiology of Insulin Deficiency and Resistance, Glycemic Targets, and the Challenges of Achievement

Pathophysiology diabetes mellitus is focused on two pillars, insulin deficiency and insulin resistance, which are different but usually interconnected abnormalities that interfere with the homeostatic symphony in glucose metabolism[20]. The major anabolic hormone is insulin secreted by the beta-cells of the pancreas, which promotes the uptake of glucose into skeletal muscle and adipose tissue, inhibits the hepatic production of glucose and prevents lipolysis and proteolysis. In complete insulin insensitivity, which occurs in type 1 diabetes and advanced type 2 diabetes, beta-cells are destroyed through autoimmune mechanisms or other mechanisms and this important signal is lost[21][22]. As a result, unopposed catabolic hormones -glucagon, cortisol, epinephrine, and growth hormone- go amok and the body becomes uncontrollably hyperglycemic, and eventually, the metabolic derangement of diabetic ketoacidosis ensues when the body breaks down fatty acids to provide energy[23].

Insulin resistance which is the hallmark of early type 2 diabetes and metabolic syndrome has a more insidious pathophysiology. In this case, there is insulin that is usually abundant, but its signal is silenced on the target tissues (muscle, liver, and fat) level. This is resisted by a complicated interaction of genetic predisposition, dysfunction of adipose tissue associated with obesity (resulting in increased free fatty acids and inflammatory cytokines such as TNF-a), and sedentary lifestyles[24][25]. The glucose production is overdone by the liver that is not responsive to the inhibitory signal of insulin. Adipose tissue secretes more fatty acids and muscle cells are resistant to glucose uptake, which also contributes to increased resistance. The initial response is hyper-secretion by the pancreatic beta-cells to the compensatory hyperinsulinemia, but this is not sustainable over the years of glucotoxicity, lipotoxicity and endoplasmic reticulum stress, the beta-cell function diminishes, and apoptotic reductions in the mass of beta-cells result in progressive relative and then absolute insulin deficiency. In this way, pathophysiology goes beyond being a simple state of isolated resistance to defect of resistance and deficiency, which forms a feedback mechanism leading to metabolic dysregulation, which in turn causes the chronic state of hyperglycemia[26].

Based on this pathophysiology, it is foremost to set clear and evidence-based glycemic control targets. The gold standard of the glycated hemoglobin (HbA1c) test which is a measure of average blood glucose over a period of three months has been in use over decades[27]. Based on randomized trials such as the DCCT and UKPDS which established that a reduction in HbA1c level lowers the incidence of complications, standard targets are typically below 7.0% in most adults, with even stricter (below 6.5) or less strict (below 8.0) targets depending on the patient's duration of diabetes, age, comorbid conditions and susceptibility to hypoglycemia. Nevertheless, HbA1c is fraught with limitations: it is a lagging average that hides the glycemic fluctuations, may be misleading when the red cells turnover is affected, and does not reveal the number of episodes of hyper and hypoglycemia that a patient lives in their life[28].



Fig: 3 Pathophysiology of Insulin Deficiency and Resistance, Glycemic Targets

The continuous glucose monitoring (CGM) and the following emphasis on Time in Range (TIR) has played a vital part in bridging this critical gap, which is, however, a complementary, but not necessarily better, metric[29]. TIR, a percentage of the duration in a target glucose range (usually 3.9-10.0 mmol/L or 70-180 mg/dL), provides a dynamic granulometric perspective of daily control. Most adult individuals are now suggested to have a target of >70% TIR, with corresponding targets of Time Below Range (TBR) (<4% at <3.9 mmol/L and <1% at under3.0 mmol/L) and Time Above Range (TAR) (<25% at >10.0 mmol/L and <5% at >13.9 mmol/L). Additional important CGM parameters are glycemic variability (the coefficient of variation should be lower than 36% to depict a stable glucose) and the Glucose Management Indicator (GMI), an estimated HbA1c by CGM[30]. This multidimensional metrics model gives us a clearer picture of the situation since a patient with HbA1c of 7.0 percent might be under-ranging with occasional lows, whereas another with the same HbA1c may be within range with glucose values at the same height-a difference that is critical when making a clinical decision and determining risk factors[31][32]. The challenges that face the attainment of these targets, however, are daunting and often intertwined in nature and are connected to the nature of insulin replacement therapy and human physiology. The most dreaded and the first is hypoglycemia. The near-normal glycemia inevitably puts someone at risk of low blood glucose, which is a side effect of insulin and its narrow therapeutic index[33][34]. Repeat lows dull the epinephrine and neurogenic effects of hypoglycemia which leads to a vicious cycle due to the pathophysiology of impaired counter-regulation and hypoglycemia unawareness, contributing to severe hypoglycemia as a life-threatening and psychologically traumatic barrier to intensive control. Fear of hypoglycemia often results in intentional sustained hyperglycemia at the expense of the long-term health to achieve the short-term security. In contrast, hyperglycemia is constantly a difficult situation because of the inability to replicate effectively physiological insulin secretion. Despite the sophisticated regimens, the matching of insulin delivery to the numerous variables influencing glucose-carbohydrate intake (usually inaccurately estimated), physical activity (which may increase glucose uptake a few hours), stress, illness, hormonal swings, and variable insulin absorption- is an algorithmic daily calculation which is likely to be inaccurate. Postprandial peaks are especially hard to manage without the subsequent lows, and the dawn phenomenon (a physiological increase in glucose in the morning caused by hormone peaks) may be intractable in raising morning values[35]. All these continuous oscillations point to the difference between open-loop insulin delivery and a normal endocrine pancreas. Beneath these physiological dilemmas lies the terrific treatment load - the complex, irrepressible and wearying self care that diabetes demands. This burden includes cognitive load of counting carbohydrates, calculating doses, and glucose patterns; physical load of injections, site changes and devices, emotional load of constant watchfulness, anxiety, and frustration, and financial load of the expense of insulin, devices, and supplies[36][37]. This diabetic distress is a highly significant, but neglected, outcome mediator. Burnout causes doses to be missed, and glucose tests to be skipped, which directly translate to poor TIR and high levels of HbA1c.

Current Insulin Delivery Systems and Their Limitations

Although the existing methods of insulin delivery can be described as a huge improvement over the crude times of insulin therapy, they are basically defined by a compromise between the complexity, cost and the extent of physiological fidelity that a system can attain. These are simple, manual injection devices at one end to complex electromechanical pumps, all characterized by significant errors of inaccuracy, support of adherence, and automated response that impede the realization of the ideal glycemic control. It is necessary to understand the development and the inherent shortcomings of syringes, pens, and pumps so that the necessity of next-generation technologies can be put into perspective[38][39]. The initial and most simple form of insulin delivery is done via syringes and vials. Although inexpensive and accessible to everyone, this approach is overloaded with serious restrictions that affect the quality of life and accuracy. To prepare a dose, one has to manually withdraw insulin in a vial into a syringe, which can easily be inaccurate, particularly with low doses that are crucial to children or patients on delicate regimens. This weakness was vividly noted by a 2024 study that showed that even expert nurses who were operating syringes had a median error of 0.6 units of 2 units dose (0.6 units) and errors up to 2 units in the worst-case scenario. Such factors as the lack of checking of air bubbles were major contributors to inaccuracy[40].

Table 2: Framework for Evaluating Advanced Insulin Delivery Systems

Evaluation Stage	Primary Methods & Settings	Key Metrics & Endpoints
Preclinical	- In Vitro Bench Testing: Accuracy, reliability. - Animal Models (Diabetic rodents/pigs): PK/PD, safety.	- Dosing accuracy. - Proof of glucose-responsive activity. - Biocompatibility.

Clinical Trials	- Phase I/II: Controlled, supervised settings (hospital). - Phase III RCT: Home use vs. standard care. - Real-World Evidence: Post-market, diverse populations.	- Primary: TIR, HbA1c. - Critical Safety: TBR (<54 mg/dL), severe hypoglycemia, DKA events. - Device Performance: % Time in closed-loop mode, usability scores.
Health Economic	- Cost-Utility Analysis (e.g., Markov models over lifetime horizon).	- Incremental Cost-Effectiveness Ratio (ICER) (Cost per QALY gained). - Impact on healthcare resource utilization.
Patient-Centered	- Validated questionnaires; qualitative interviews.	- Patient-Reported Outcomes (PROs): Diabetes distress, treatment satisfaction, quality of life. - Psychosocial impact.

In addition to accuracy, the technique is not portable or discrete, which in most cases leads to social stigma and overdose in public areas. It is also very technical and requires good hand dexterity and eyesight thus posing some difficulty to some users. Conventional insulin pens have been designed in order to overcome most of these inefficiencies by integrating a syringe and an insulin vial in one device. They have great benefits by being available in reusable pens with replaceable cartridges or in disposable pre-filled units[41][42]. They have better dosing precision with a dial-a-dose design, are more compact and discrete, and less injection pain is typically related to them, which results in patient satisfaction and compliance. There is clinical evidence in their favor; the Standards of Care of the American Diabetes Association provide that insulin pens are a preferred method in most situations as opposed to insulin vials and syringes because they are easy to use and deliver accurate dosage. Nevertheless there are still restrictions. They turn out to be more costly per unit of insulin than a vial, do not allow mixing of two or more types of insulin in a single injection, and even after their advantages, continue to impose a persistent cognitive and behavioural load due to the requirement of multiple daily injections[42][43].

Continuous Subcutaneous Insulin Infusion (CSII) through insulin pumps is the most technologically advanced and widely available one. These are small electrical devices that provide quick acting insulin in 24 hour round the clock through a subcutaneous cannula instead of the long-acting insulin injection[44][45]. CSII therapy provides unprecedented flexibility with users being able to change the basal rates according to various times of the day (e.g. to overcome the dawn phenomenon) and precise meal-time boluses. It has the potential to result in improved glycemic control, less glucose variability and less risk of hypoglycemia compared to Multiple Daily Injections (MDI). It has been found that patient satisfaction in CSII is always higher because it provides more freedom in the timing of meals, physical exercises, and daily activities. Due to an example, users express a high level of change in lifestyle flexibility and sleep quality. However, there are its own problems associated with CSII. It is the costliest delivery system, forms a permanent physical connection with the body which may affect clothing, sleep and sex, and has the chances of technical breakdown (e.g., pump failure, kinked cannulas, site infections). It is also a very technical requirement and is a very demanding task on the part of the user[46].

The evolution of improved insulin delivery devices is a multidimensional undertaking to overcome the constraints of traditional treatment in the attempt to develop more physiologic, automated and user-friendly alternatives. This development is characterized by the coming together of continuous glucose monitoring, advanced control algorithms, and new delivery systems, all of which drive towards the long-held ambition of a fully automated artificial pancreas.

Closed-Loop (Automated Insulin Delivery) Systems

These systems combine a continuous glucose monitor (CGM), a control program, and an insulin pump into a single automated ecosystem. The algorithm which is the brain within the system takes the real-time CGM data and calculates and commands the pump to deliver insulin after every few minutes. Their development has been gradual as they started with low-glucose suspend (LGS) systems that ceased the delivery of insulin when it predicted hypoglycemia. This advanced to predictive low-glucose suspend (PLGS) and later to hybrid closed-loop (HCL) systems which automatic 24/7 administration of basal insulin, but necessitate manual user announcements of meals. One major randomized controlled trial showed that Time in Range (+2.4 hours/day) and less hypoglycemia were dramatically improved with hybrid closed-loop use than sensor-augmented pump therapy[47]. Relevant commercial HCL systems currently in use are the Medtronic MiniMed 780G that has automatic correction privy; the Tandem t:slim X2 with Control-IQ and the tubeless Omnipod 5 System. The next stage of development is completely closed loop systems that aim at removing the announcements of meals, sometimes using more rapidly acting insulins or the use of an adjunctive hormone such as glucagon[48].

Smart Insulin Pens and Connected Caps

These devices convert injection-based care to digital by bridging the gap between multiple daily injections (MDI) and pump therapy. Connected caps can also be used with conventional pens (e.g. Novo Nordisk NovoPen 6 and Echo Plus or Companion Medical InPen) and provide dose recording, priming, and bolus calculators[49]. They can time doses, compute insulin-on-board, and be able to sync the data to smartphone applications and cloud solutions to be viewed by the users and care teams. This feature is a solution to major adherence and accuracy gaps in MDI through mitigation of manual logging errors and data-driven decision-making to optimize therapy, in effect introducing a sort of "connectivity and decision support to injection therapy[50].



Fig: 3 Evolution from Open-Loop to Closed-Loop Insulin Delivery

Patch Pumps and Tubeless Pumps

These pumps are intended with a low profile and are easy to use, with all components (reservoir, drive mechanism, infusion set) being contained within one pod which is attached directly to the skin, thus removing the use of tubing. Such devices as Omnipod series are operated wirelessly through a special handheld controller or smartphone[51][52]. Their benefits with a patient-oriented approach are the easy wearability, the simplicity of care site management, and perceived lesser stigma in many cases. Moderner generations are intrinsically compatible with CGM to create hybrid closed-loop assesses, such as the Omnipod 5, and therefore automated insulin delivery becomes more common to individuals who dislike traditional tubed pumps.

Insulin Formulations Response to Glucose.

This ground-breaking technology is sometimes called smart insulin, and it entails the design of the insulin molecule or its carrier to have an autonomous effect on its own activity depending on the level of blood glucose[53]. The principles are the application of the glucose oxidase enzyme to generate an acidic microenvironment, the use of phenylboronic acid polymers, which bind glucose, or the use of glucose binding molecules like concanavalin A. Such triggers are incorporated into formulation approaches including hydrogels capable of swelling and delivering insulin, subcutaneous nanocarrier, or dissolvable patches of microneedles. Although it remains in preclinical and initial clinical phases, there is a promise of this technology and the future is that with one injection, basal coverage with automatic meal-time reactions, the mechanical pumps might not be needed anymore[54].

Implantable Insulin Pumps

These implants are inserted into the peritoneal cavity and they provide long-term intraperitoneal delivery which is more similar to the pancreatic insulin release into the portal vein. There is some promise in such systems as the Medtronic MiniMed 780G implantable pump demonstrating the potential of such systems in those with very unstable type 1 diabetes. Nevertheless, all these technical problems like the presence of foreign-body response causing fibrotic encapsulation, the necessity of no less than periodic surgical filling, and catheter blockage have restricted the extensive use[55]. Their use is very specialized and patient selection is normally done when the patient is not able to control with the advanced subcutaneous therapies.

Insulin by Oral and Inhalation.

The goal of non-invasive pathways should be to enhance physiologic profile and adherence. Oral insulin has significant obstacles: it is destroyed in the stomach by enzymes rapidly and is not absorbed into the intestines. Enhanced encapsulation methods which involve polymeric or lipid nanocarriers and hydrogels are in development in order to encapsulate insulin and enhance its uptake. Rapid acting prandial insulin (e.g., Afrezza) is already commercially available as inhaled insulin. It has a very rapid onset, but has difficulties with dosing and pulmonary long-term safety. There is an active clinical trial environment of next-generation oral formulations that is supported by the option of transformative patient convenience[56].

Artificial Pancreas and Algorithmic Control.

The control algorithm determines the performance of any automated system due to its sophistication. Control carried out with early systems was Proportional-Integral-Derivative (PID). The current systems mostly rely on the Model Predictive Control (MPC) that predicts the future glucose and optimizes the insulin by the mathematical representation of the interaction between glucose and insulin in the patient. Studies are done on the use of fuzzy logic and artificial intelligence to manage uncertainty. The major areas requiring improvement include integration of meal-announcement plans better, exercise detection, and adaptation and dual-hormonal (insulin and glucagon) systems to achieve tight control. The ultimate objective is the concept of personalization and adaptive learning where the algorithm will constantly adjust its parameters to reflect the changing physiology of the person, and transforming a one-size-fits-all type of pancreas into an actual custom one [57].

Preclinical and Clinical Evaluation Methods

Advanced insulin delivery systems demand rigorous evaluation and this demands a multi-stage pipeline through controlled laboratory and animal studies, to large human clinical studies, and lastly through evaluation of real world value, cost, and patient experience. Every phase uses unique methodologies to provide critical answers to questions concerning the safety, effectiveness, and overall influence of a system[58][59]. Preclinical testing Preclinical testing starts with bench testing in vitro which is a strict test of the delivery accuracy, dynamic response time, and mechanical reliability of a device under physiological simulated conditions. This is then succeeded by experiments in diabetic animal models (e.g. chemically induced diabetic rodents, spontaneously diabetic NOD mice or diabetic pigs). The models give the first in vivo evidence of concept of glucose-responsive activity, pharmacodynamics/pharmacokinetics, and preliminary biocompatibility, and safety, which is the key to human trials. These systems are designed in a clinical trial format that takes the form of a phased format but is modified to suit complicated medical equipment[60]. The phase I trials are oriented on the safety, feasibility and initial algorithm performance within highly monitored environments. Phase II testing is broadened to larger populations to better dose refine and obtain initial effectiveness. Phase III trials are major studies, randomized controlled trials (RCTs), that compare the new system to the standard care (e.g., sensor-augmented pump therapy) to conclusively demonstrate that the new system is superior in glycemic outcomes. After the regulatory approval, real-world evidence studies are significant and will confirm how the system works in various and daily settings not limited to rigorous measures of an RCT[61].



Fig: 4 Critical barriers to the adoption of integrated digital delivery in the construction industry

The measures of glycemic control have changed considerably. Although HbA1c is still a major primary endpoint in the case of long-term glycemic burden, the metrics offered by Continuous Glucose Monitor (CGM) have become predominant. The first efficacy endpoint is the Time in Range (TIR, 70-180 mg/dL), whereas co-primary safety and efficacy outcomes are the Time Below Range (TBR) and Time Above Range (TAR). Secondary endpoints will comprise glycemic variability (Coefficient of Variability), mean glucose, and a collection of patient-reported outcomes (PROs). Endpoints of safety and efficacy are carefully monitored. The paramount ones are hypoglycemia events (Level 2 <54 mg/dL and Level 3 severe events) and diabetic ketoacidosis (DKA) risk[. The negative events associated with the device (e.g., infusion site infection, pump failure) and [62]verall system usability and reliability (per cent of time when the system is in closed-loop mode) are typical.

Lastly, there is the overall assessment on health economics and life quality. Cost-effectiveness studies (usually based on cost per-QALY (Quality-Adjusted Life Year) models) evaluate the long-term value of the system by balancing the cost of the system with the result in the form of improved life expectancy and quality due to a decrease in complications[63]. At the same time, diabetes-specific quality-of-life measures (e.g., DQOL, DSQOLS) and treatment-satisfaction, treatment-burden, and psychosocial-impact measures quantify the human benefit of glucose-numbers, which means that the technology really enhances living. Ideally, contemporary assessment builds an interwoven evidence ecosystem: preclinical evidence justifies human trials, RCTs evidence shows effective controlled use, real world studies show practical usage, economic and PRO assessments evidence demonstrate holistic worth, and it is all that makes a system become its final usage in diabetes care[64][65].

Conclusion

Finally, the rising pandemic of diabetes worldwide due to the pathophysiological facts of insulin deficiency and resistance demands a radical approach to managing the disease. The long-term experience has proven that close glycemic regulation is the primary factor to avoid disastrous complications, but standard pumps with multiple injections every day and traditional ones that are simply open-loop delivery systems are fundamentally inefficient. Their hyper reactive quality combined with an excessively heavy cognitive and emotional load impose a burden of freedom that renders most of them incapable of meeting suggested targets. The next-generation insulin delivery systems, especially hybrid closed-loop technology are a paradigm shift to this treatment stalemate. These systems establish a proactive biofeedback loop by combining remote glucose measurements, smart control algorithms, and remote insulin delivery devices. They significantly enhance important outcomes, such as a greater time-in-range and less hypoglycemia, and substantially reduce diabetes distress through automating daily micro-decisions. In spite of the difficulties of high initial investment and the necessity of a user interaction, the prospects of cost-effective use in the long term with the elimination of complications are evident. With these systems progressing to autonomy and intelligence, they present the best opportunity of curbing the world burden of diabetes towards less dangerous, healthier and more free lives of millions of people.

References

1. Sherr, J. L., Heinemann, L., Fleming, G. A., Bergenstal, R. M., Bruttomesso, D., Hanaire, H., ... & Phillip, M. (2023). Automated insulin delivery: Benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European Association for the Study of Diabetes and the American Diabetes Association. *Diabetologia, 66*(1), 3–22. https://doi.org/10.1007/s00125-022-05744-z
2. Kesavadev, J., Saboo, B., Krishna, M. B., & Krishnan, G. (2020). Evolution of insulin delivery devices: From syringes, pens, and pumps to DIY artificial pancreas. *Diabetes Therapy, 11*(6), 1251–1269. https://doi.org/10.1007/s13300-020-00831-z
3. Silva, J., Da Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., ... & Cohen, O. (2022). Real-world performance of the MiniMed™ 780G system: First report of outcomes from 4120 users. *Diabetes Technology & Therapeutics, 24*(2), 113–119. https://doi.org/10.1089/dia.2021.0203
4. Newman, C., Hartnell, S., Wilinska, M., Alwan, H., & Hovorka, R. (2023). Real-world evidence of the Cambridge hybrid closed-loop app with a novel real-time continuous glucose monitoring system. *Journal of Diabetes Science and Technology*, 1, 165–168. https://doi.org/10.1177/19322968231187915
5. Chico, A., Navas De Solís, S., Lainez, M., Rius, F., & Cuesta, M. (2023). Efficacy, safety, and satisfaction with the Accu-Chek Insight with Diabeloop closed-loop system in subjects with type 1 diabetes: A multicenter real-world study. *Diabetes Technology & Therapeutics, 25*(4), 242–249. https://doi.org/10.1089/dia.2022.0449
6. Forlenza, G. P., Carlson, A. L., Galindo, R. J., Kruger, D. F., Levy, C. J., McGill, J. B., ... & Bode, B. W. (2022). Real-world evidence supporting Tandem Control-IQ hybrid closed-loop success in the Medicare and Medicaid type

1 and type 2 diabetes populations. *Diabetes Technology & Therapeutics, 24*(11), 814–823. https://doi.org/10.1089/dia.2022.0206

7. Noor, N., Kamboj, M. K., Triolo, T., Polsky, S., McDonough, R. J., Demeterco-Berggren, C., ... & Ebekozien, O. (2022). Hybrid closed-loop systems and glycemic outcomes in children and adults with type 1 diabetes: Real-world evidence from a U.S.-based multicenter collaborative. *Diabetes Care, 45*(8), e118–e119. https://doi.org/10.2337/dc22-0329
8. Bismuth, É., Tubiana-Rufi, N., Rynders, C. A., Dalla-Vale, F., Bonnemaison, E., Coutant, R., ... & Madoumier, M. (2024). Sustained 3-year improvement of glucose control with hybrid closed loop in children with type 1 diabetes while going through puberty. *Diabetes Care, 47*(9), 1696–1703. https://doi.org/10.2337/dc24-0916
9. Zeng, B., Gao, L., Yang, Q., Jia, H., & Sun, F. (2023). Automated insulin delivery systems in children and adolescents with type 1 diabetes: A systematic review and meta-analysis of outpatient randomized controlled trials. *Diabetes Care, 46*(12), 2300–2307. https://doi.org/10.2337/dc23-0504
10. van den Heuvel, T., Kolassa, R., Keuthage, W., Kroeger, J., Ré, R., de Portu, S., ... & Smith, H. B. (2024). Advanced hybrid closed loop in adult population with type 1 diabetes: A substudy from the ADAPT randomized controlled trial in users of real-time continuous glucose monitoring. *Journal of Diabetes Science and Technology, 18*(5), 1132–1138. https://doi.org/10.1177/19322968231161320
11. Crabtree, T. S. J., Griffin, T. P., Yap, Y. W., Narendran, P., Gallen, G., Furlong, N., ... & Andrews, R. C. (2023). Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: A real-world observational study. *Diabetes Care, 46*(10), 1831–1838. https://doi.org/10.2337/dc23-0635
12. Lee, T. T. M., Collett, C., Bergford, S., Hartnell, S., Scott, E. M., Lindsay, R. S., ... & Murphy, H. R. (2023). Automated insulin delivery in women with pregnancy complicated by type 1 diabetes. *New England Journal of Medicine, 389*(17), 1566–1578. https://doi.org/10.1056/NEJMoa2303911
13. Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., ... & Peters, A. L. (2021). The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care, 44*(11), 2589–2625. https://doi.org/10.2337/dci21-0043
14. Griffin, T. P., Gallen, G., Hartnell, S., Crabtree, T., Holloway, M., Gibb, F. W., ... & Mellor, D. (2023). UK's Association of British Clinical Diabetologist's Diabetes Technology Network (ABCD-DTN): Best practice guide for hybrid closed-loop therapy. *Diabetic Medicine, 40*(7), 1–21. https://doi.org/10.1111/dme.15078
15. American Diabetes Association Professional Practice Committee. (2024). 7. Diabetes technology: Standards of care in diabetes-2024. *Diabetes Care, 47*(Suppl 1), S126–S144. https://doi.org/10.2337/dc24-S007
16. Bassi, M., Teliti, M., Lezzi, M., Iosca, A., Strati, M. F., Carmisciano, L., ... & Maghnie, M. (2022). A comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes. *Frontiers in Endocrinology, 12*, 802419. https://doi.org/10.3389/fendo.2021.802419
17. Bassi, M., Patti, L., Silvestrini, I., Strati, M. F., Ponzano, M., Minuto, N., ... & Maghnie, M. (2023). One-year follow-up comparison of two hybrid closed-loop systems in Italian children and adults with type 1 diabetes. *Frontiers in Endocrinology, 14*, 1099024. https://doi.org/10.3389/fendo.2023.1099024
18. Schütz, A., Rami-Merhar, B., Schütz-Fuhrmann, I., Blauensteiner, N., Baumann, P., Pöttler, T., ... & Fritsch, M. (2024). Retrospective comparison of commercially available automated insulin delivery with open-source automated insulin delivery systems in type 1 diabetes. *Journal of Diabetes Science and Technology*. Advance online publication. https://doi.org/10.1177/19322968241230106
19. Navas Moreno, V., Sebastian-Valles, F., Sampedro-Nuñez, M., Lahera Vargas, M.,

Marazuela, M., & Arranz Martin, J. A. (2023). Patient satisfaction in three advanced hybrid closed-loop systems at 6 months of treatment in adults with type 1 diabetes mellitus: A follow-up study. *Endocrinología, Diabetes y Nutrición, 70*(8), 548–555. https://doi.org/10.1016/j.endinu.2023.06.005

20. Jeyaventhan, R., Gallen, G., Choudhary, P., & Hussain, S. (2021). A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G. *Diabetes, Obesity and Metabolism, 23*(8), 1989–1994. https://doi.org/10.1111/dom.14439
21. Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., ... & Phillip, M. (2019). Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. *Diabetes Care, 42*(8), 1593–1603. https://doi.org/10.2337/dci19-0028
22. Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., ... & the iDCL Trial Research Group. (2019). Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. *New England Journal of Medicine, 381*(18), 1707–1717. https://doi.org/10.1056/NEJMoa1907863
23. Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., ... & Hovorka, R. (2018). Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. *The Lancet, 392*(10155), 1321–1329. https://doi.org/10.1016/S0140-6736(18)31947-0
24. Pharmd, P., Vorrink, L., Da Silva, J., Choudhary, P., Kolassa, R., Keuthage, W., ... & Heinemann, L. (2022). Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): A randomised controlled study. *The Lancet Diabetes & Endocrinology, 10*(10), 720–731. https://doi.org/10.1016/S2213-8587(22)00212-1
25. Beck, R. W., Kanapka, L. G., Breton, M. D., Brown, S. A., Wadwa, R. P., Buckingham, B. A., ... & the Control-IQ Technology Research Group. (2023). A meta-analysis of randomized trial outcomes for the t:slim X2 insulin pump with control-IQ technology in youth and adults from age 2 to 72. *Diabetes Technology & Therapeutics, 25*(5), 329–342. https://doi.org/10.1089/dia.2022.0558
26. Di Molfetta, S., Di Gioia, L., Caruso, I., Cignarelli, A., Green, S. C., Natale, P., ... & Natalicchio, A. (2024). Efficacy and safety of different hybrid closed loop systems for automated insulin delivery in people with type 1 diabetes: A systematic review and network meta-analysis. *Diabetes/Metabolism Research and Reviews, 40*(6), e3842. https://doi.org/10.1002/dmrr.3842
27. Choudhary, P., Arrieta, A., van den Heuvel, T., Castañeda, J., Smaniotto, V., & Cohen, O. (2024). Celebrating the data from 100,000 real-world users of the MiniMed™ 780G system in Europe, Middle East, and Africa collected over 3 years: From data to clinical evidence. *Diabetes Technology & Therapeutics, 26*(S3), 32–37. https://doi.org/10.1089/dia.2023.0433
28. Benhamou, P. Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., ... & the OpenAPS consortium. (2019). Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: A 12-week multicentre, open-label randomised controlled crossover trial. *The Lancet Digital Health, 1*(1), e17–e25. https://doi.org/10.1016/S2589-7500(19)30003-2
29. Gera, S., Rearson, A., Baker, G., Douvas, J. L., Alicea-Trelles, N., Gallop, R. J., ... & Patton, S. R. (2025). Changes in 90-day time in range among youth with type 1 diabetes initiating different automated insulin delivery systems. *The Journal of Clinical Endocrinology & Metabolism, 15*. Advance online publication. https://doi.org/10.1210/clinem/dgaf006
30. Bisio, A., Gonder-Frederick, L., McFadden, R., Cherñavvsky, D., Voelmle, M., Pajewski, M., ... & Shepard, J. A. (2022). The impact of a

recently approved automated insulin delivery system on glycemic, sleep, and psychosocial outcomes in older adults with type 1 diabetes: A pilot study. *Journal of Diabetes Science and Technology, 16*(3), 663–669. https://doi.org/10.1177/193229682098687 9

31. Beato-Víbora, P. I., Chico, A., Moreno-Fernandez, J., Bellido-Castañeda, V., Nattero-Chávez, L., Picón-César, M. J., ... & the Spanish HCL Consortium. (2023). A multicenter prospective evaluation of the benefits of two advanced hybrid closed-loop systems in glucose control and patient-reported outcomes in a real-world setting. *Diabetes Care, 47*(1), 216–234. https://doi.org/10.2337/dc23-1355
32. Renard, E., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., ... & the SAPHTI study group. (2023). Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: A randomized controlled trial. *Diabetes Care, 46*(12), 2180–2188. https://doi.org/10.2337/dc23-0685
33. Amigó, J., Ortiz-Zúñiga, Á., de Urbina, A. M. O., Sánchez, M., Dos-Santos, M., Abad, M., ... & Miralles, J. A. (2023). Switching from treatment with sensor augmented pump to hybrid closed loop system in type 1 diabetes: Impact on glycemic control and neuropsychological tests in the real world. *Diabetes Research and Clinical Practice, 201*, 110730. https://doi.org/10.1016/j.diabres.2023.110730
34. Hood, K. K., Schneider-Utaka, A. K., Reed, Z. W., Buckingham, B. A., Cobry, E., DeBoer, M. D., ... & Messer, L. H. (2024). Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology. *Diabetes Research and Clinical Practice, 208*, 111114. https://doi.org/10.1016/j.diabres.2024.111114
35. Navas Moreno, V., Sebastian-Valles, F., Sampedro-Nuñez, M., Lahera Vargas, M., Marazuela, M., & Arranz Martin, J. A. (2023). Satisfacción del paciente en tres sistemas avanzados de asa cerrada híbrida a los 6 meses de tratamiento en adultos con diabetes mellitus tipo 1: Un estudio de seguimiento. *Endocrinología, Diabetes y Nutrición, 70*(8), 548–555. https://doi.org/10.1016/j.endinu.2023.06.005
36. Hwang, B.-G., Shan, M., & Looi, K. Y. (2020). Integrated digital delivery: Implementation status and project performance in the Singapore construction industry. *Journal of Cleaner Production, 262*, 121396. https://doi.org/10.1016/j.jclepro.2020.121396
37. Liu, Z., Chi, Z., Osmani, M., & Demian, P. (2021). Transition from building information modeling (BIM) to integrated digital delivery (IDD) in sustainable building management: A knowledge discovery approach based review. *Journal of Cleaner Production, 291*, 125223. https://doi.org/10.1016/j.jclepro.2020.125223
38. Succar, B. (2009). Building information modelling framework: A research and delivery foundation for industry stakeholders. *Automation in Construction, 18*(3), 357–375. https://doi.org/10.1016/j.autcon.2008.10.003
39. Mesa, H. A., Molenaar, K. R., & Alarcón, L. F. (2016). Exploring performance of the integrated project delivery process on complex building projects. *International Journal of Project Management, 34*(7), 1089–1101. https://doi.org/10.1016/j.ijproman.2016.05.007
40. Wuni, I. Y., Shen, G. Q., & Osei-Kyei, R. (2020). Critical success factors for management of the early stages of prefabricated prefinished volumetric construction project life cycle. *Engineering, Construction and Architectural Management, 27*(9), 2315–2333. https://doi.org/10.1108/ECAM-07-2019-0377
41. Zheng, X., Le, Y., Chan, A. P., Hu, Y., & Li, Y. (2016). Review of the application of social network analysis (SNA) in construction project management research. *International Journal of*

Project Management, 34(7), 1214–1225. https://doi.org/10.1016/j.ijproman.2016.06.005

42. Yuan, M., Li, Z., Li, X., & Luo, X. (2021). Managing stakeholder-associated risks and their interactions in the life cycle of prefabricated building projects: A social network analysis approach. *Journal of Cleaner Production, 323*, 129102. https://doi.org/10.1016/j.jclepro.2021.129102
43. Yang, R. J., & Zou, P. X. (2014). Stakeholder-associated risks and their interactions in complex green building projects: A social network model. *Building and Environment, 73*, 208–222. https://doi.org/10.1016/j.buildenv.2013.12.014
44. Sadiq, R., & Rodriguez, M. J. (2004). Fuzzy synthetic evaluation of disinfection by-products – A risk-based indexing system. *Journal of Environmental Management, 73*(1), 1–13. https://doi.org/10.1016/j.jenvman.2004.05.003
45. Ameyaw, E. E., & Chan, A. P. (2015). Evaluation and ranking of risk factors in public–private partnership water supply projects in developing countries using fuzzy synthetic evaluation approach. *Expert Systems with Applications, 42*(12), 5102–5116. https://doi.org/10.1016/j.eswa.2015.02.039
46. Kelvin-Agwu MC, Mustapha AY, Mbata AO, Tomoh BO, Forkuo AY. Development of Smart Insulin Delivery Systems for Improving Diabetes Management in Public Health. Development. 2025 Mar;9(3):19-32.
47. Olorunsola EO, Alozie MF, Davies KG, Adedokun MO. Advances in the science and technology of insulin delivery: A review. Journal of Applied Pharmaceutical Science. 2021 Jul 18;11(8):184-91.
48. Garg SK, McVean JJ. Development and future of automated insulin delivery (AID) systems. Diabetes Technology & Therapeutics. 2024 Mar 1;26(S3):1-6.
49. Castle JR, DeVries JH, Kovatchev B. Future of automated insulin delivery systems. Diabetes technology & therapeutics. 2017 Jun 1;19(S3):S-67.
50. Nawaz MS, Shah KU, Khan TM, Rehman AU, Rashid HU, Mahmood S, Khan S, Farrukh MJ. Evaluation of current trends and recent development in insulin therapy for management of diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017 Dec 1;11:S833-9.
51. Karol AB, O'Malley G, Fallurin R, Levy CJ. Automated insulin delivery systems as a treatment for type 2 diabetes mellitus: a review. Endocrine Practice. 2023 Mar 1;29(3):214-20.
52. Lawal OP, Taiye AF, Okafor CE, Elechi KW, Orobator ET, Kolapo TJ, Olaniyi AO, Mandal M, Olaniyi HI. The Automated Insulin Delivery System in Nigeria: Advances, Challenges, And Future Prospects in Closed-Loop Insulin Delivery Systems. Journal of Medical Science, Biology, and Chemistry. 2025 May 3;2(1):64-74.
53. Renard E. Automated insulin delivery systems: from early research to routine care of type 1 diabetes. Acta Diabetologica. 2023 Feb;60(2):151-61.
54. Jacobs PG, Levy CJ, Brown SA, Riddell MC, Cinar A, Boughton CK, Breton MD, Dassau E, Forlenza G, Henderson RJ, Hovorka R. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. Journal of Diabetes Science and Technology. 2025 Jul;19(4):937-49.
55. Jones HC, Trawley S, Jenkins AJ, MacIsaac RJ, Kong YW, Morrison D, O'Neal DN. Automated Insulin Delivery Beyond Glycemic Outcomes: Endpoints and Evidence. Diabetes Technology & Therapeutics. 2025 Nov 14:15209156251390831.
56. Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, Evans ML, Wertli MM, Coll AP, Stettler C, Hovorka R. Closed-loop insulin delivery for glycemic control in noncritical care. New England Journal of Medicine. 2018 Aug 9;379(6):547-56.
57. Joshi SR, Kesavadev J, Saboo B, Parikh R, Chawla M, Gupta A, Bhartia M, Shankar A, Basanth A, Krishnan G. Advancements in Insulin Delivery Technology: A Journey of

Evolution. International Journal of Diabetes and Technology. 2023 Jan 1;2(1):7-15.

58. Thabit H, Lal R, Leelarathna L. Automated insulin dosing systems: advances after a century of insulin. Diabetic Medicine. 2021 Dec;38(12):e14695.
59. Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. Journal of Managed Care Pharmacy. 2012 Jul;18(6 Supp A):1-7.
60. Considine EG, Sherr JL. Real-world evidence of automated insulin delivery system use. Diabetes Technology & Therapeutics. 2024 Mar 1;26(S3):53-65.